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osting by EAbstract Two simple and sensitive high performance liquid chromatographic (HPLC) methods
have been developed for the simultaneous determination of three different quinolones: enroﬂoxacin,
lomeﬂoxacin and oﬂoxacin in their pure and dosage forms, one with reversed phase HPLC and the
other with ion-pair HPLC. In reversed phase HPLC, method (A), the mobile phase consists of
2.18% aqueous solution of KH2PO4 with pH adjusted to 2.4 ± 0.2 with acetonitrile (80:20; v/v),
the mobile phase pumped at ﬂow rate of 1.2 ml min1. A Neucleosil C18 column (10 lm, 100 A˚),
250 mm length · 4.6 mm diameter was utilized as stationary phase. Detection was affected spectro-
photometrically at 294 nm. While in ion-pair HPLC, method (B), the mobile phase was aqueous
solution of 0.65% sodium perchlorate and 0.31% ammonium acetate adjusted to pH 2.2 ± 0.2 with
orthophosphoric acid: acetonitrile (81:19; v/v), the mobile phase pumped at ﬂow rate of 1.5 ml min1.
A l bondapack C18 column (10 lm, 100 A˚), 250 mm length · 4.6 mm diameter was utilized as sta-
tionary phase. Detection was affected spectrophotometrically at 294 nm. Linearity ranges for enro-
ﬂoxacin, lomeﬂoxacin and oﬂoxacin were 4.0–108, 7.0–112 and 8.0–113 lg ml1, respectively using
method A and 8.0–112, 7.0–112 and 5.0–105 lg ml1, respectively applying method B. Minimum
detection limits obtained were 0.013, 0.023 and 0.035 lg ml1 for enroﬂoxacin, lomeﬂoxacin and
oﬂoxacin, respectively using method A, and 0.028, 0.023 and 0.011 lg ml1 using method B.m (A.S. Amin).
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F250 A.S. Amin et al.The proposed methods were further applied to the analysis of enroﬂoxacin in injection and tablets
containing the oﬂoxacin and lomeﬂoxacin drugs, and the results were satisﬁed.
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Enroﬂoxacin (Enro), lomeﬂoxacin (Lome) and oﬂoxacin (Oﬂo)
are ﬂuorinated 4-quinolone (Fig. 1) and have a wide spectrum
of antibacterial activity (Monk and Campoli-Richards, 1987).
Oﬂoxacin is among the ﬂuoroquinolones considered promising
for the treatment of ocular infections (Borrmann et al., 1988).
An ophthalmic solution of oﬂoxacin was introduced for the
topical treatment of ocular infections caused by susceptible
gram-negative and gram-positive bacteria (Gwon, 1992). Anal-
ysis of ﬂuoroquinolones in pharmacokinetic studies has rlied
mainly on a variety of microbiological method (Wise et al.,
1986) which are non-selective and imprecise compared with
more recent approaches using high performance liquid chro-
matography (HPLC) (Basci et al., 1996; Nemutlu et al.,
2007; Suna et al., 2007). Selective determination of ﬂouroqui-
nolone derivatives from tablets by reverse-phase was investi-
gated (Shinde et al., 1998; Marilyn et al., 2007; Espinosa-
Mansilla et al., 2005). Quantitative determination of Enro,
Lome and Oﬂo in pharmaceutical dosage, bulk drugs and pro-
cess monitoring of enroﬂoxacin by RP-HPLC was studied
(Argekar et al., 1996). A simple, rapid and sensitive HPLC
method was developed for the assay of Enro in raw material
and injection (Souza et al., 2002; Salehzadeh et al., 2007).
The fate of Enro present in raw sewage at a swine-breeding
facility was investigated by liquid–liquid extraction and re-
versed phase liquid chromatography with photodiode array
detection (Pierini et al., 2004). Determination of a series of
quinolone antibiotics using liquid chromatography–mass spec-
trometry was studied (Ballesteros et al., 2004; Santoro et al.,
2006). A rapid and simple procedure for determination of
enroﬂoxacin and ciproﬂoxacin in bovine milk and plasma is
described (Idowu and Peggins, 2004). The aim of the present
work is to develop a simple, rapid, sensitive and reliable HPLC
assay procedures to quantify oﬂoxacin, lomeﬂoxacin and enro-
ﬂoxacin in their pharmaceutical dosage forms.
2. Experimental
2.1. Apparatus
Chromatographic separation and detection was performed on
high performance liquid chromatography (HPLC) system
which consisted of pump (WATERS Model 515), an autosam-igure 1 The chemical structurepler (WATERS Model 717) and a Dual k absorbance detector
(WATERS model 2489) with 10 mm path length cell. The data
were recorded on a personal computer, using the manufacturer
software package (Millennium 32, Version 3.02, WATERS). A
Jenway Instruments (Germany) pH meter was used for pH
control; the instrument has previously been calibrated against
standard buffer solutions of pH 2.0, 4.0 and 7.0.
2.2. Drugs
Enroﬂoxacin (99.92%), lomeﬂoxacin hydrochloride (99.95%)
and oﬂoxacin (99.52%) were kindly supplied by Egyptian
International Pharmaceutical Industries Company (EIPICO),
Egypt, Pharmaceutical dosage forms were bought from local
market.
2.3. Reagents
 All reagents were obtained from VWR Chemicals (Pool,
England).
 Methanol (HiPerSolv for HPLC).
 Acetonitrile (HiPerSolv).
 Potassium dihydrogen phosphate (AnalaR).
 Orthophosphoric acid (about 85%, AnalaR), were obtained
from VWR Chemicals (Pool, England).
 Millipore 0.45 lm nylon membrane ﬁlter (USA).
 Sodium perchlorate (GPR) and ammonium acetate crystals
(AnalaR).
 The high purity water was prepared using WATERS Ultra
pure water system (WATERS, USA).2.4. Solution preparations
2.4.1. Stock and working standards solutions
– Enro, Lome and Oﬂo stock solutions containing 1.0 mg
ml1 of each in methanol were prepared separately by
weighing 100 mg each of Enro, Lome and Oﬂo in 100 ml
volumetric ﬂask and diluted to the mark with the same
solvent (standards stock solutions).
– Working standards solutions of Enro, Lome and Oﬂo were
prepared separately by diluting 5.0 ml from each standard
stock solution, to 100 ml with mobile phase A or B forof three pure drug materials.
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was ﬁltered through 0.45 lm membrane ﬁlter.2.4.2. Preparation of buffer solutions
A. Phosphate solution: A 21.8 g of potassium dihydrogen
phosphate was dissolved in 1000 ml of puriﬁed water
and the pH was adjusted to 2.4 with orthophosphoric
acid (85%).
B. Perchlorate solution: A 3.1 g of ammonium acetate and
6.5 g of sodium perchlorate were dissolved in 1000 ml
of puriﬁed water. The pH of resulted solution was
adjusted to 2.2 with orthophosphoric acid (85%).2.5. Application of pharmaceutical dosage forms
2.5.1. For method (A) reversed phase HPLC
Tablets: 20 tablets were weighed and ﬁnely powdered. To a
quantity of powdered tablets equivalent 200 mg of Lome or
200 mg Oﬂo, 150 ml of methanol were added and dispersed
with aid of sonication for 5 min, shacked for 15 min. A sufﬁ-
cient of methanol was added to produce 200 ml, mixed. TheFigure 2 Separation of Enro, Lome and Oﬂo – Amixture was centrifuged and 5.0 ml of supernatant liquid were
diluted to 100 ml with mobile phase A. A portion or resulted
solution was ﬁltered through 0.45 lm membrane ﬁlter.
Injection: Accurately, 2.0 ml of injection were transferred to
200 ml volumetric ﬂask, mixed with 150 ml of methanol and
sonicated for 5.0 min. A sufﬁcient of methanol was added to
produce 200 ml, mixed. Resulted solution (5.0 ml) were diluted
to 100 ml with mobile A. A portion of resulted solution was
ﬁltered through 0.45 lm membrane ﬁlter.
2.5.2. For method (B) ion-paring mobile phase
As preparation withmethod (A) but the second dilutionwas per-
formed with mobile phase (B). The methods were applied for
analysis ofmore thanone typeof tablets and injectionspurchased
from local marketing and the results were listed in Table 6.
2.6. Chromatographic conditions
2.6.1. Method (A) reversed phase HPLC
The chromatographic separation was performed on a C18 col-
umn (10 lm, 100 A˚), 250 mm length · 4.6 mm diameter parti-
cle size, Neucleosil C18 reversed-phase column packed with– mobile method (A) and mobile method (B).
252 A.S. Amin et al.dimethyloctadecyl-silyl bonded amorphous silica. The mobile
phase was consists of 2.18% aqueous solution of KH2PO4 with
pH adjusted to 2.4 ± 0.2 with acetonitrile (80:20; v/v), the mo-
bile phase pumped at ﬂow rate of 1.2 ml min1 the mobileFigure 3 Chromatograms obtaiphase was ﬁltered through 0.45 lm nylon ﬁlter, degassed for
15 min then pumped at ﬂow rate 1.2 ml min1. The column
was kept at 20.0 ± 2.0 C during the analysis; the detection
wavelength was 294 nm and the injection volume was 20 ll.ned during selectivity (cont.).
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The mobile phase was aqueous solution of 0.65% sodium per-
chlorate and 0.31% of ammonium acetate adjusted to pH
2.2 ± 0.2 with orthophosphoric acid:acetonitrile (81:19; v/v).
The mobile phase was ﬁltered through 0.45 lm nylon mem-
brane ﬁlter, degassed for 15 min then pumped at ﬂow rate
was 1.5 ml min1. The column was kept at 20.0 ± 2.0 C dur-
ing the analysis; the detection wavelength was 294 nm and the
injection volume was 20 ll. A l bondapack C18 column
(10 lm, 100 A˚), 250 mm length · 4.6 mm diameter was utilized
as stationary phase. Detection was affected spectrophotometri-
cally at 294 nm.
3. Results and discussions
The cationic nature of Enro, Lome and Oﬂo leads to broad
asymmetric peaks in RP-HPLC with aqueous-organic mobile
phases and conventional C18 columns, because of the ionic
interaction with the alkyl-bonded reversed-phase packing.
Also using of methanol or acetonitrile lead to unresolved
and high tailing peaks.
3.1. Method (A) reversed phase HPLC
In order to affect the simultaneous elution of three peaks un-
der isocratic conditions the mobile phase composition (organic
modiﬁer, ﬂow rate, ionic strength and pH) has been investi-
gated. The reversed phase HPLC method (A) proposed using
of low pH solution with acetonitrile to block the residual sila-
nol interaction and reduce tailing, orthophosphoric acid is
used here in pH adjustment. The mobile phase (A) was consists
of 2.18% aqueous solution of KH2PO4 with pH adjusted to
2.4 ± 0.2 with acetonitrile (80:20; v/v). The mobile phase com-
positions were optimized by changing the pH range (2.0–3.0)
in addition to changing temperature (20–30 C). Under the de-
scribed conditions, the three components were deﬁned, re-
solved and free from tailing, the tailing factors were <1.3
for all peaks. The elution order were Oﬂo (tR = 10.6), Lome
(tR = 13.3) and Enro (tR = 16.9) (Fig. 2).
3.2. Method (B) Ion-paring mobile phase
An ion-pairing substance as sodium perchlorate solution with
acetonitrile was used to decrease the residual silanol interac-
tion and decrease tailing, the mobile phase was an aqueous
solution of 0.65% sodium perchlorate and 0.31% of ammo-Table 1 Characteristics of the proposed methods used in assay of E
Parameter RP-HPLC (method A)
Enro Lome
Linearity range/lg ml1 4.0–108 7.0–112
Slope 2.16 · 103 7.5 · 103
Intercept (a) 11.5 · 103 3.9 · 103
Correlation coeﬃcient 0.99994 0.99960
Detection limit/lg ml1 0.013 0.023
Quantiﬁcation limit/lg ml1 0.044 0.077
Capacity factor 15.92 12.31
Tailing factor 1.25 1.25
Theoretical plate no. 3272 2804
Regression equation = A= a+ bC, where A is the area under peak andnium acetate adjusted to pH 2.2 ± 0.2 with orthophosphoric
acid: acetonitrile (81:19; v/v), the mobile phase composition
were optimized by changing the pH range (2.0–3.0) in addition
to temperature changed from 20–30 C. Under the described
conditions the three components were well deﬁned, resolved
and free from tailing, the tailing factors were <1.2 for all
peaks. The elution order were Oﬂo (tR = 10.2), Lome
(tR = 12.5) and Enro (tR = 16.0), (Fig. 2).
3.3. Validity of the methods
3.3.1. Selectivity
For chromatographic methods, selectivity is the ability of the
method to accurately measure the analyte in presence of all po-
tential sample components. The selectivity of both methods
was checked by two ways, the ﬁrst way by comparison the
chromatograms obtained from dosage forms samples and the
corresponding placebo (Fig. 3). It is clear that there is no sig-
niﬁcant peak in the placebo chromatogram at retention time of
three separated peaks is appeared in the test chromatogram.
The second way to check the selectivity of both methods was
standard addition method in which a known concentration
of the analyte were added to previously analyzed pharmaceu-
tical preparation (Table 7).
3.3.2. Linearity
The linear correlation between area under peaks and com-
pound concentrations was checked for each component using
both methods. Data for six different concentrations was ran-
ged in (4.0–108 lg ml1) for Enro, (7.0–112 lg ml1) for Lome
and (8.0–113 lg ml1) for Oﬂo with method (A), and (8.0–
112 lg ml1) for Enro, (7.0–112 lg ml1) for Lome, and
(5.0–105 lg ml1) for Oﬂo with method (B) were collected
and analyzed. Each solution was injected for ﬁve times then
the least square method was used for calculation of the slope,
intercept and correlation coefﬁcient (r) for compounds with
both mobile phases. The correlation between the analyte con-
centration and peak area is described by linear regression
equations with high value of correlation coefﬁcient (r) all re-
sults were listed in Table 1.
3.3.3. Limit of detection and limit of quantiﬁcation
The limits of detection and of quantiﬁcation were calculated in
accordance with 3.3 s/m and 10 s/m criteria (ICH, 1995),
respectively. Where s is standard deviation of peak area (for
ﬁve replicates) for analyte and (m) is the slope of calibrationnro, Lome and Oﬂo.
Ion-pairing (method B)
Oﬂo Enro Lome Oﬂo
8.0–113 8.0–112 7.0–112 5.0–105
16.5 · 103 5.4 · 103 0.5 · 103 1.2 · 103
4.7 · 103 1.7 · 103 3.1 · 103 3.8 · 103
0.99990 0.99997 0.99942 0.99988
0.035 0.028 0.023 0.011
0.117 0.094 0.077 0.037
9.63 15.30 11.53 9.18
1.32 1.18 1.19 1.17
2649 4232 4001 3889
a, is the intercept.
Table 2 Evaluation of accuracy of the proposed methods.
Drugs Theoretical conc. RP-HPLC method A Ion-pairing method B
Founda Recovery RSD% Founda Recovery RSD%
Enro 15.03 14.97 99.6 0.25 15.21 101.2 0.21
40.08 40.27 100.5 0.25 39.93 99.6 0.50
45.09 45.38 100.7 0.68 45.55 101.0 0.48
50.10 50.49 100.8 0.10 50.99 101.8 0.36
55.11 54.59 99.1 0.04 55.15 100.1 0.25
87.68 88.65 101.1 0.23 88.36 100.8 0.27
Lome 14.94 14.89 99.7 0.47 15.01 100.5 0.11
39.84 40.18 100.8 0.40 39.66 99.6 0.75
44.82 45.45 101.4 0.10 45.05 100.5 0.33
49.80 49.57 99.5 0.70 50.05 100.5 0.40
54.78 54.81 100.1 0.36 54.81 100.1 0.67
87.15 88.68 101.8 0.81 87.93 100.9 0.67
Oﬂo 15.18 15.23 100.3 0.63 15.07 99.3 0.10
40.48 40.76 100.7 0.60 40.62 100.3 0.63
45.54 45.62 100.2 0.58 45.49 99.9 0.55
50.60 50.19 99.2 0.43 50.84 100.5 0.33
55.66 56.19 101.0 0.36 55.44 99.6 0.57
88.55 88.24 99.7 0.10 88.96 100.5 0.40
a Average of ﬁve determinations.
254 A.S. Amin et al.plot, determination from the linearity investigation. The LOD
and LOQ obtained were listed in Table 1.
3.4. Accuracy
In order to determine the accuracy of the proposed methods
solution contains six different concentration of Enro, Lome
and Oﬂo were prepared and analyzed. The recoveries obtained
among studied concentrations range of each Enro, Lome and
Oﬂo were 100.28 ± 0.78%, 100.54 ± 0.93% and 100.17 ±
0.66% with mobile phase A and 100.75 ± 0.78%, 100.33 ±
0.46% and 100.01 ± 0.49% with mobile phase B, respectively.
The results obtained from these investigations were summa-
rized in Table 2.Table 3 Summary of repeatability (intra-day) and reproducibility
phase (A) and mobile phase (B).
Theoretical conc.
(lg ml1)
Intra-day
Recovery ± RSD After 2 days
A B A B
Enroﬂoxacin
40.16 100.98 ± 0.42 100.43 ± 0.41 101.00 ± 0.81 100.20
50.20 100.97 ± 0.13 101.27 ± 0.13 101.45 ± 0.24 100.78
55.22 99.84 ± 0.87 100.24 ± 0.74 99.47 ± 0.77 100.34
Lomeﬂoxacin
39.92 100.64 ± 0.91 100.31 ± 0.10 99.91 ± 0.43 100.24
49.90 99.49 ± 0.98 100.01 ± 0.28 99.61 ± 0.60 100.09
54.89 100.54 ± 0.76 100.26 ± 0.45 99.94 ± 0.16 99.68 ±
Oﬂoxacin
40.24 100.45 ± 0.31 100.04 ± 0.13 100.32 ± 0.22 100.73
50.30 99.34 ± 0.55 99.89 ± 0.26 100.39 ± 0.82 100.67
55.33 100.69 ± 0.17 100.73 ± 0.39 100.98 ± 0.25 100.523.5. Precision
The precision of the methods expressed as the closeness of
agreement (degree of scatter) between a series of measurements
obtained from multiple sampling of the same homogeneous
sample under the prescribed conditions. Repeatability and
reproducibility expressed as RSD% were characterized by
spread data from replicate determination. The intra-day preci-
sion (repeatability) of both methods were evaluated by analysis
by the mean of ﬁve replicates of three different reference stan-
dard solution containing 80%, 100% and 110% of the labeled
amount of Enro (100 mg/ml) in Avitryl injection, Lome
(400 mg/tablet) in Lomax tabs and Oﬂo (200 mg/tablet) in
Oﬂicin tabs. The inter-day precision (reproducibility) of both(inter-day) precision data for Enro, Lome and Oﬂo with mobile
Inter-day amount recovered ± RSD
After 4 days After 8 days
A B A B
± 0.20 100.78 ± 0.52 99.46 ± 0.58 99.80 ± 0.23 98.96 ± 0.23
± 0.79 101.15 ± 0.17 100.78 ± 0.21 99.13 ± 0.89 99.65 ± 0.64
± 0.14 99.21 ± 0.19 100.45 ± 0.22 98.47 ± 0.66 98.32 ± 0.68
± 0.14 100.14 ± 0.31 99.75 ± 0.26 99.41 ± 0.48 98.87 ± 0.65
± 0.23 99.14 ± 0.30 99.93 ± 0.14 98.82 ± 0.04 99.02 ± 0.45
0.23 100.04 ± 0.47 99.83 ± 0.18 98.45 ± 0.24 98.94 ± 0.24
± 0.16 100.14 ± 0.12 100.49 ± 0.53 99.45 ± 0.33 99.19 ± 0.61
± 0.37 99.83 ± 0.25 99.56 ± 0.50 98.21 ± 0.53 98.33 ± 0.55
± 0.13 100.16 ± 0.33 100.12 ± 0.27 99.08 ± 0.19 98.59 ± 0.57
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ence solution (second dilution; i.e. 100%) of the labeled
amount on four different days and results obtained from this
analysis were listed in Table 3 as mean recovery (%). The re-
sults showed that there is no difference either within day or be-
tween days implying that the repeatability and reproducibility
of both methods was good. The results obtained were com-
pared statistically by Student’s t-test (for accuracy), and vari-
ance ratio F-test (for precision) (Miller and Miller, 2000), at
95% conﬁdence level. The results showed that the t- and F-val-
ues were lower than the critical values indicating that there was
no signiﬁcant difference between the proposed methods.
3.6. Robustness
The methods were found to be robust although small deliber-
ate changes in method conditions did have some effect on the
chromatographic behavior of the solutes. The chromato-
graphic condition investigated was mobile phase composition,
pH, ﬂow rate, column temperature and detected wavelength.
The results of robustness analysis showed that although small
changes in the mobile phase pH has no signiﬁcant effect on the
retention time for Enro, Lome and Oﬂo with both methods.
The changes in the ﬂow rate, leading to increase in the peak
tailing and increase the broadening of analyte peaks (Table
4). Changing in the column temperature has larger effect on
the chromatographic behavior of the three peaks with both
methods than mobile phase, pH and ﬂow rate. While the
reduction in the concentration of sodium perchlorate in meth-Table 4 Effect of column temperature and mobile phase pH on the
A and B.
Parameters Mobile phase
2.0 2.2 2.4 2
Method A: RP-HPLC
Enroﬂoxacin
K 15.50 15.87 15.92 1
As 1.27 1.25 1.25 1
N 3232 3282 3272 3
Lomeﬂoxacin
K 12.00 12.29 12.31 1
As 1.32 1.15 1.25 1
N 2700 2844 2804 2
Oﬂoxacin
K 9.57 9.60 9.63 9
As 1.29 1.33 1.32 1
N 2600 2635 2649 2
Method B: Ion-pair-HPLC
Enroﬂoxacin
K 15.27 15.30 15.22 1
As 1.20 1.18 1.20 1
N 4230 4232 4221 4
Lomeﬂoxacin
K 11.50 11.53 11.47 1
As 1.18 1.19 1.20 1
N 3885 4001 3985 3
Oﬂoxacin
K 9.08 9.18 9.23 9
As 1.18 1.17 1.20 1
N 3885 3889 3875 3
K, capacity factor; N, no. of theoretical plates; As, asymmetry factor.od (B) leads to partial deterioration in the behavior of three
solutes. Also the decrease in the concentration of buffer solu-
tion in mobile phase (A) lead to deterioration of the chromato-
graphic behavior of both solutes. Finally altering of the
wavelength detection has no effect on the chromatographic
behavior of both solutes with the two methods.
3.7. System suitability
According to USP (The United State Pharmacopoeia, 2007),
system suitability tests are an integral part of liquid chromato-
graphic method. System suitability tests are used to verify that
resolution and reproducibility were adequate for analysis per-
formed. The parameters of this test are column efﬁciency
(number of theoretical plates), asymmetry of chromatographic
peak, peak resolution factor, and repeatability as RSD of peak
area for ﬁve injections and reproducibility of retention as RSD
of retention time. The results of these tests and their accep-
tance criteria according to USP regulation were listed in Table
5. From the obtained results on comparison with the speciﬁca-
tion set for the methods can be used to draw conclusion about
the suitability of system for analysis.
3.8. Analytical applications
Pharmaceutical formulations containing Enro, Lome and Oﬂo
were analyzed successfully by the proposed method with a
good recovery. Results are recorded in Table 6 conﬁrming that
the proposed method is not liable to interference by injectionchromatographic behavior of Enro, Lome and Oﬂo with method
Column temperature
.6 3.0 20 C 25 C 30 C
5.94 16.31 15.92 15.96 15.43
.31 1.35 1.25 1.20 1.20
255 3200 3272 3266 3221
2.34 12.88 12.31 12.23 11.88
.26 1.35 1.25 1.23 1.27
837 2577 2804 2824 2800
.65 9.78 9.63 9.58 9.44
.34 1.35 1.32 1.33 1.40
637 2599 2649 2630 2588
5.66 15.78 15.30 15.49 15.86
.23 1.29 1.18 1.20 1.29
189 4100 4232 4225 4155
1.66 11.79 11.53 11.55 12.55
.25 1.21 1.19 1.22 1.20
975 3844 4001 3900 3891
.29 9.77 9.18 9.22 9.79
.29 1.21 1.17 1.12 1.10
537 3493 3889 3879 3895
Table 6 Determination of Enro, Lome and Oﬂo in pharmaceutical dosage forms.
Drugs Company Active Labeled (mg) Method A Method B
Founda (mg) Recovery (%) RSD (%) Founda (mg) Recovery (%) RSD (%)
Enrocxin 10% Inj Alexandria Enro 100 mg/ml 101.80 101.80 0.56 101.46 101.46 0.63
Avitryl 10% Inj AVICO Enro 100 mg/ml 102.47 102.57 0.24 102.15 102.15 0.47
Lomex Tab Sigma Lome 400 mg 404.04 101.01 0.49 404.80 101.20 0.75
Lomax Tab Julphar Lome 400 mg 401.48 100.37 0.2 399.96 99.99 0.34
Tarivid Tab Hoechst Oﬂo 200 mg 200.32 100.16 0.84 200.80 100.40 0.66
Oﬂicin Memphis Oﬂo 200 mg 203.22 101.61 0.65 201.88 100.94 0.46
a Average of ﬁve determinations.
Table 7 Determination of Enro, Lome and Oﬂo in pharmaceutical dosage forms applying the standard addition technique.
Dosage form Taken (lg/ml) Added (lg/ml) Method A Method B
Founda (lg/ml) Recovery (%) Founda (lg/ml) Recovery (%)
Enrocxin 10% Inj (Enro) 20.36 20.06 40.18 99.4 40.10 99.2
30.09 50.83 100.8 51.00 101.1
40.12 60.60 100.2 60.99 100.9
Lomax Tab (Lome) 20.07 20.02 39.93 99.6 40.44 100.9
30.03 50.45 100.7 50.71 101.2
40.04 61.02 101.5 59.57 99.1
Oﬂicin (Oﬂo) 20.32 20.08 40.64 100.6 39.96 98.9
30.12 51.20 101.5 50.85 100.8
40.16 60.24 99.6 61.45 101.6
a Average of ﬁve determinations.
Table 5 Summary of system suitability tests.
Parameter Method A Method B
Enro Lome Oﬂo Enro Lome Oﬂo
K 15.92 12.31 9.63 15.30 11.53 9.18
Rb 3.0 2.8 2.8 3.8 3.2 3.2
N 3272 2804 2649 4232 4001 3884
As 1.25 1.25 1.32 1.18 1.19 1.17
RSDa (peak areas) 0.79 0.68 0.65 0.82 0.76 0.51
RSDa (retention time) 0.29 0.42 0.42 0.24 0.17 0.19
K, capacity factor; N, no. of theoretical plates; R, resolution factor; As, asymmetry factor.
a RSD for ﬁve determinations.
b The resolution factor (R) calculated to the nearest peak in order.
256 A.S. Amin et al.and tablet ﬁllers, excipients and additives usually formulated
with injection and tablets. The standard addition method in
which a known concentration of the analyte were added to pre-
viously analyzed pharmaceutical preparation (Table 7). The
proposed method is highly sensitive; therefore, it could be used
easily for the routine analysis of pure form and in its pharma-
ceutical formulations.
4. Conclusion
Two simple, sensitive, accurate, reproducible and precise liquid
chromatographic methods for assay of Enro, Lome and Oﬂo
in pure and bulk forms have been developed and validated.
The advantages of the proposed methods are lower detection
limits and higher quantiﬁcation limit this permit wide rangeof analysis. Furthermore, these methods are capable to deter-
mine one of the three components in the presence of other two.
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